SCHEMBL2827683

SCHEMBL2827683

NNC(=O)c1cnc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21084204 0.81
SCHEMBL5161349 0.80 AOC1 (0.47)
SCHEMBL6662772 0.79
SCHEMBL21268151 0.79
SCHEMBL7522000 0.77 NPC1 (0.50)
SCHEMBL18912254 0.77 ACACB (0.45)
SCHEMBL18912250 0.77 TP53 (0.50)
SCHEMBL18912256 0.77 KDM4E (0.47)
SCHEMBL16950289 0.76 TP53 (0.49)
SCHEMBL826324 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 CN disclosed
EP-4229050-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-08-23 EP disclosed
WO-2022078407-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 WO disclosed
CN-109715615-A Biaryl methyl heterocycles 蒙特利尔大学 2019-05-03 CN disclosed
CN-105175421-B Midbody compound and application thereof for synthesis of selective NK-3 receptor antagonists 欧歌达有限公司 2018-07-13 CN disclosed
CN-104610159-B A kind of imidazoles hydrazides 01 derivatives and its preparation method and application 台州职业技术学院 2018-04-13 CN disclosed
CN-107108554-A It is used for the phenyl amino benzimidazole of 1 cyclohexyl 2 for treating tumour as MIDH1 inhibitor 拜耳医药股份有限公司 2017-08-29 CN disclosed
CN-103906750-B9 Novel chiral N-acyl-5, 6,7, (8-substituted) -tetrahydro- [1, 2,4] triazolo [4, 3-a ] pyrazines as selective NK-3 receptor antagonists, pharmaceutical compositions, methods for use in NK-3 receptor mediated diseases and chiral synthesis thereof 欧洲筛选有限公司 2016-10-12 CN disclosed
CN-103906750-B Novel chiral N-acyl-5, 6,7, (8-substituted) -tetrahydro- [1, 2,4] triazolo [4, 3-a ] pyrazines as selective NK-3 receptor antagonists, pharmaceutical compositions, methods for use in NK-3 receptor mediated diseases and chiral synthesis thereof 欧洲筛选有限公司 2016-08-24 CN disclosed
CN-102906093-A Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders EUROSCREEN SA 2013-01-30 CN disclosed
EP-1937688-B1 IMIDAZO BENZODIAZEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
US-7507729-B2 for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine HOFFMANN-LA ROCHE INC. (US) 2009-03-24 US disclosed
WO-2008157273-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
WO-2008095912-A2 ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES NYCOMED GMBH (DE) 2008-08-14 WO disclosed
EP-1937688-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO disclosed
WO-2007042421-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed
US-20070082890-A1 Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT 2007-04-12 US disclosed
EP-0277384-A2 1H-imidazole-5-carboxylic acid derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1988-08-10 EP disclosed